Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies

Laurence J.N. Cooper, Zaid Al-Kadhimi, David DiGiusto, Michael Kalos, David Colcher, Andrew Raubitschek, Steve J. Forman, Michael C. Jensen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stem cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents.

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalBlood Cells, Molecules, and Diseases
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Adoptive Immunotherapy
B-Lymphocytes
T-Lymphocytes
Tissue Donors
Neoplasms
Hematopoietic Stem Cells
Transplants
Leukemia
Leukocytes
Cytotoxic T-Lymphocytes
Graft vs Host Disease
Lymphoma
Clinical Trials
Antigens

Keywords

  • Leukemia
  • T cell
  • Toxicity

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. / Cooper, Laurence J.N.; Al-Kadhimi, Zaid; DiGiusto, David; Kalos, Michael; Colcher, David; Raubitschek, Andrew; Forman, Steve J.; Jensen, Michael C.

In: Blood Cells, Molecules, and Diseases, Vol. 33, No. 1, 01.01.2004, p. 83-89.

Research output: Contribution to journalArticle

Cooper, Laurence J.N. ; Al-Kadhimi, Zaid ; DiGiusto, David ; Kalos, Michael ; Colcher, David ; Raubitschek, Andrew ; Forman, Steve J. ; Jensen, Michael C. / Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. In: Blood Cells, Molecules, and Diseases. 2004 ; Vol. 33, No. 1. pp. 83-89.
@article{90e15ee2dbd74cc5a7810153285b21c6,
title = "Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies",
abstract = "The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stem cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents.",
keywords = "Leukemia, T cell, Toxicity",
author = "Cooper, {Laurence J.N.} and Zaid Al-Kadhimi and David DiGiusto and Michael Kalos and David Colcher and Andrew Raubitschek and Forman, {Steve J.} and Jensen, {Michael C.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.bcmd.2004.03.003",
language = "English (US)",
volume = "33",
pages = "83--89",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies

AU - Cooper, Laurence J.N.

AU - Al-Kadhimi, Zaid

AU - DiGiusto, David

AU - Kalos, Michael

AU - Colcher, David

AU - Raubitschek, Andrew

AU - Forman, Steve J.

AU - Jensen, Michael C.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stem cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents.

AB - The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stem cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents.

KW - Leukemia

KW - T cell

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=3042562007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042562007&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2004.03.003

DO - 10.1016/j.bcmd.2004.03.003

M3 - Article

C2 - 15223016

AN - SCOPUS:3042562007

VL - 33

SP - 83

EP - 89

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 1

ER -